[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"urothelial-carcinoma-of-the-urinary-bladder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:urothelial-carcinoma-of-the-urinary-bladder":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100578964","bladder-epicheck-european-haematuria-study-100578964",false,"NCT06818136","Bladder EpiCheck European Haematuria Study","Evaluation of the Efficacy of Bladder EpiCheck® for the Primary Detection of Urothelial Carcinoma in Subjects Presenting With Haematuria","Inclusion Criteria:\n\n1. Participants aged 45 years or older\n2. Participants who are willing and able to provide written informed consent and adhere to study procedures\n3. Participants presenting with visible and\u002For non-visible haematuria within 6 months prior to study enrollment\n4. Participants scheduled to undergo standard of care cystoscopy for urinary bladder examination within 60 days after study enrollment\n5. Participants who are able to produce at least 10 ml of voided urine\n\nExclusion Criteria:\n\n1. Participants with history of urothelial cancer in the bladder and\u002For upper urinary tract\n2. Participants who had prior cystoscopy for haematuria within the past 2 years\n3. Participants previously enrolled in this study\n4. Participants treated for prostate cancer within the last 12 months\n5. Participants treated for kidney cancer within the last 12 months\n6. Participants with untreated urinary tract infection\n7. Participants with symptomatic urinary tract stones (e.g. flank pain)\n8. Participants on dialysis for end stage renal failure\n9. Participants with a long term urinary catheter\n10. Pregnancy (self-reported)\n11. Participants who, because of medical status, or frailty is not expected to be able to complete the full diagnostic pathway","ALL","45 Years",{"count":19,"type":20},800,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to further validate the sensitivity and specificity of Bladder EpiCheck in primary detection of urothelial carcinoma in participants aged 45 years or older presenting with haematuria, compared to cystoscopy and pathology, if performed.\n\nParticipants will provide a voided urine sample, and data from standard of care haematuria work-up will be collected.",[24,25,26,27,28],"Hematuria","Cystoscopy","Urothelial Carcinoma Bladder","Urothelial Carcinoma of the Renal Pelvis and Ureter","Urothelial Carcinoma of the Urinary Bladder",[30,31,32],"urine test","methylation","primary detection","RECRUITING","2026-01-21",{"date":36,"type":37},"2026-01-22","ACTUAL",{"date":39,"type":37},"2025-06-20",{"date":41,"type":20},"2026-12",{"name":43,"class":44},"Nucleix Ltd.","INDUSTRY",5]